Skip to content

Study · Randomized controlled trial · n = 35 · 2019

5 results

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.

Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH

American journal of physiology. Renal physiology24 Oct 2018Cited by 50 (Europe PMC)

PMID30353743 (opens in a new tab)DOI10.1152/ajprenal.00432.2018 (opens in a new tab)PepBankPUB-30353743
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, lixisenatide increased absolute and fractional sodium, chloride, and potassium excretion after breakfast versus insulin glulisine.

    In plain wordsIn patients with diabetes, lixisenatide increased absolute and fractional sodium, chloride, and potassium excretion after breakfast versus insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAbsolute and fractional sodium, chloride and potassium excretion
    Study

    n = 35

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 μg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After a standardized breakfast, lixisenatide increased absolute and fractional excretions of sodium, chloride, and potassium and increased urinary pH.
    1 context sentence
    Summary · context
    In this secondary analysis of a randomized trial, we determined the renal tubular effects of 8-wk treatment with 20 μg lixisenatide, a short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight T2DM-patients on stable insulin glargine background therapy
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight patients with diabetes, lixisenatide increased postprandial urinary pH versus insulin glulisine.

    In plain wordsLixisenatide increased urinary pH after breakfast versus insulin glulisine in patients with diabetes.

    Peptide
    Lixisenatide
    Outcome
    IncreaseUrinary pH
    Study

    n = 35

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 μg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After a standardized breakfast, lixisenatide increased absolute and fractional excretions of sodium, chloride, and potassium and increased urinary pH.
    1 context sentence
    Summary · context
    In this secondary analysis of a randomized trial, we determined the renal tubular effects of 8-wk treatment with 20 μg lixisenatide, a short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight T2DM-patients on stable insulin glargine background therapy
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, lixisenatide reduced absolute and fractional magnesium, calcium, and phosphate excretion versus insulin glulisine.

    In plain wordsIn patients with diabetes, lixisenatide reduced absolute and fractional magnesium, calcium, and phosphate excretion versus insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseAbsolute and fractional magnesium, calcium and phosphate excretion
    Study

    n = 35

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 μg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In contrast, lixisenatide reduced absolute and fractional excretions of magnesium, calcium, and phosphate.
    1 context sentence
    Summary · context
    In this secondary analysis of a randomized trial, we determined the renal tubular effects of 8-wk treatment with 20 μg lixisenatide, a short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight T2DM-patients on stable insulin glargine background therapy
  4. 04HumanRandomized controlled trialMechanism

    In patients with diabetes, lixisenatide increased phosphorylated NHE3 in urinary vesicles versus insulin glulisine at week 8.

    In plain wordsLixisenatide increased phosphorylated NHE3 in urinary vesicles versus insulin glulisine at week 8.

    Peptide
    Lixisenatide
    Outcome
    IncreasePhosphorylated NHE3 in urinary vesicles
    Study

    n = 35

    Comparator
    Insulin glulisine
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 μg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 8, patients treated with lixisenatide had significantly more phosphorylated sodium-hydrogen exchanger isoform 3 (NHE3) in urinary extracellular vesicles than those on insulin glulisine treatment, which suggested decreased NHE3 activity in the proximal tubule.
    1 context sentence
    Summary · context
    In this secondary analysis of a randomized trial, we determined the renal tubular effects of 8-wk treatment with 20 μg lixisenatide, a short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight T2DM-patients on stable insulin glargine background therapy
  5. 05HumanObservational studyEfficacy outcome

    In patients with diabetes, postprandial blood pressure rose with lixisenatide and partly explained urinary changes.

    In plain wordsPostprandial blood pressure rose with lixisenatide in patients with diabetes and partly explained urinary changes.

    Peptide
    Lixisenatide
    Outcome
    IncreasePostprandial blood pressure
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 μg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    A rise in postprandial blood pressure with lixisenatide partly explained the changes in the urinary excretion of sodium, potassium, magnesium, and phosphate and the changes in urinary pH.
    1 context sentence
    Summary · context
    In this secondary analysis of a randomized trial, we determined the renal tubular effects of 8-wk treatment with 20 μg lixisenatide, a short-acting (prandial) GLP-1RA, versus titrated once-daily insulin glulisine in 35 overweight T2DM-patients on stable insulin glargine background therapy

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.